AAAAAA
Results: 1-25/29
Authors:
Landowski, TH
Moscinski, L
Burke, R
Buyuksal, I
Painter, JS
Goldstein, S
Dalton, WS
Citation: Th. Landowski et al., CD95 antigen mutations in hematopoietic malignancies, LEUK LYMPH, 42(5), 2001, pp. 835
Authors:
Dalton, WS
Citation: Ws. Dalton, Therapeutic modalities, CURR OPIN O, 13(6), 2001, pp. 451-452
Authors:
Damiano, JS
Hazlehurst, LA
Dalton, WS
Citation: Js. Damiano et al., Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and gamma-irradiation, LEUKEMIA, 15(8), 2001, pp. 1232-1239
Authors:
Niu, GL
Shain, KH
Huang, M
Ravi, R
Bedi, A
Dalton, WS
Jove, R
Yu, H
Citation: Gl. Niu et al., Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest, CANCER RES, 61(8), 2001, pp. 3276-3280
Authors:
Hazlehurst, LA
Valkov, N
Wisner, L
Storey, JA
Boulware, D
Sullivan, DM
Dalton, WS
Citation: La. Hazlehurst et al., Reduction in drug-induced DNA double-strand breaks associated with beta 1 integrin-mediated adhesion correlates with drug resistance in U937 cells, BLOOD, 98(6), 2001, pp. 1897-1903
Authors:
Grad, JM
Bahlis, NJ
Reis, I
Oshiro, MM
Dalton, WS
Boise, LH
Citation: Jm. Grad et al., Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells, BLOOD, 98(3), 2001, pp. 805-813
Authors:
Diaz, JI
Pow-Sang, JM
Mora, LB
Seigne, JD
Cantor, AB
Dalton, WS
Citation: Ji. Diaz et al., Cytometric analysis of Fas and Bcl-2 expression in normal prostatic epithelium and prostate cancer, UROL ONCOL, 5(4), 2000, pp. 149-154
Authors:
Alexanian, R
Anderson, K
Barlogie, B
Berenson, J
Dalton, WS
Kyle, RA
Citation: R. Alexanian et al., Sydney E. Salmon, CLIN CANC R, 6(1), 2000, pp. 316-316
Authors:
Shtil, AA
Turner, JG
Dalton, WS
Yu, H
Citation: Aa. Shtil et al., Alternative pathways of cell death to circumvent pleiotropic resistance inmyeloma cells: Role of cytotoxic T-lymphocytes, LEUK LYMPH, 38(1-2), 2000, pp. 59-70
Authors:
Damiano, JS
Dalton, WS
Citation: Js. Damiano et Ws. Dalton, Integrin-mediated drug resistance in multiple myeloma, LEUK LYMPH, 38(1-2), 2000, pp. 71-81
Authors:
Dalton, WS
Citation: Ws. Dalton, Cellular determinants of drug response provide new targets for cancer therapy, CURR OPIN O, 12(6), 2000, pp. 541-542
Authors:
Shain, KH
Landowski, TH
Dalton, WS
Citation: Kh. Shain et al., The tumor microenvironment as a determinant of cancer cell survival: a possible mechanism for de novo drug resistance, CURR OPIN O, 12(6), 2000, pp. 557-563
Authors:
Hazlehurst, LA
Damiano, JS
Buyuksal, I
Pledger, WJ
Dalton, WS
Citation: La. Hazlehurst et al., Adhesion to fibronectin via beta 1 integrins regulates p27(kip1) levels and contributes to cell adhesion mediated drug resistance (CAM-DR), ONCOGENE, 19(38), 2000, pp. 4319-4327
Authors:
Fishman, MN
Dalton, WS
Citation: Mn. Fishman et Ws. Dalton, Considerations in the management of myeloma, ONCOLOGY-NY, 14(11A), 2000, pp. 72-81
Authors:
Shain, KH
Landowski, TH
Buyuksal, I
Cantor, AB
Dalton, WS
Citation: Kh. Shain et al., Clonal variability in CD95 expression is the major determinant in Fas-mediated, but not chemotherapy-mediated apoptosis in the RPMI 8226 multiple myeloma cell line, LEUKEMIA, 14(5), 2000, pp. 830-840
Authors:
Alexanian, R
Anderson, K
Barlogie, B
Berenson, J
Dalton, WS
Kyle, RA
Citation: R. Alexanian et al., Sydney E. Salmon, MD - In Memoriam, J CL ONCOL, 18(1), 2000, pp. 1-2
Authors:
Kudoh, K
Ramanna, M
Ravatn, R
Elkahloun, AG
Bittner, ML
Meltzer, PS
Trent, JM
Dalton, WS
Chin, KV
Citation: K. Kudoh et al., Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray, CANCER RES, 60(15), 2000, pp. 4161-4166
Authors:
Scheffer, GL
Maliepaard, M
Pijnenborg, ACLM
van Gastelen, MA
de Jong, MC
Schroeijers, AB
van der Kolk, DM
Allen, JD
Ross, DD
van der Valk, P
Dalton, WS
Schellens, JHM
Scheper, RJ
Citation: Gl. Scheffer et al., Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines, CANCER RES, 60(10), 2000, pp. 2589-2593
Authors:
Ross, DD
Yang, WD
Abruzzo, LV
Dalton, WS
Schneider, E
Lage, H
Dietel, M
Greenberger, L
Cole, SPC
Doyle, LA
Citation: Dd. Ross et al., Atypical multidrug resistance: Breast cancer resistance protein messenger RNA expression in mitroxantrone-selected cell lines, J NAT CANC, 91(5), 1999, pp. 429-433
Authors:
Dalton, WS
Scheper, RJ
Citation: Ws. Dalton et Rj. Scheper, Lung resistance-related protein: Determining its role in multidrug resistance, J NAT CANC, 91(19), 1999, pp. 1604-1605
Authors:
Dalton, WS
Citation: Ws. Dalton, The tumor microenvironment as a determinant of drug response and resistance, DRUG RESIST, 2(5), 1999, pp. 285-288
Authors:
Catlett-Falcone, R
Landowski, TH
Oshiro, MM
Turkson, J
Levitzki, A
Savino, R
Ciliberto, G
Moscinski, L
Fernandez-Luna, JL
Nunez, G
Dalton, WS
Jove, R
Citation: R. Catlett-falcone et al., Constitutive activation of Stat3 signaling confers resistance to apoptosisin human U266 myeloma cells, IMMUNITY, 10(1), 1999, pp. 105-115
Authors:
Rimsza, LM
Campbell, K
Dalton, WS
Salmon, S
Willcox, G
Grogan, TM
Citation: Lm. Rimsza et al., The major vault protein (MVP), a new multidrug resistance associated protein, is frequently expressed in multiple myeloma, LEUK LYMPH, 34(3-4), 1999, pp. 315
Authors:
Hazlehurst, LA
Foley, NE
Gleason-Guzman, MC
Hacker, MP
Cress, AE
Greenberger, LW
De Jong, MC
Dalton, WS
Citation: La. Hazlehurst et al., Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line, CANCER RES, 59(5), 1999, pp. 1021-1028
Authors:
Landowski, TH
Shain, KH
Oshiro, MM
Buyuksal, I
Painter, JS
Dalton, WS
Citation: Th. Landowski et al., Myeloma cells selected for resistance to CD95-mediated apoptosis are not cross-resistant to cytotoxic drugs: Evidence for independent mechanisms of caspase activation, BLOOD, 94(1), 1999, pp. 265-274